Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO(TM) for the Treatment of Gaucher Disease
Published in Medical Letter on the CDC and FDA, November 1st, 2009
The corrected release reads: PROTALIX BIOTHERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PHASE III CLINICAL TRIAL OF UPLYSO™ FOR THE TREATMENT OF GAUCHER DISEASE Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- American Academy of Neurology
New guidelines identify best treatments to help ALS patients live longer, easier - Harvard School of Public Health
Vaccinating boys against human papillomavirus not cost-effective - Louisiana State University Health Sciences Center
LSUHSC's England plays key role in developing new ALS treatment guidelines - Thomas Jefferson University
Researchers identify mechanism that helps bacteria avoid destruction in cells - Wiley-Blackwell
Study identifies significant savings on venous leg ulcer dressings - Alzheimer Disease
EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
